Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: An experience sampling study

Journal of Clinical Psychiatry

Volumn 72, Issue 10, 2011, Pages 1397-1404

  Lataster, Johan ^a   Van Os, Jim ^a,b   De Haan, Lieuwe ^c   Thewissen, Viviane ^a,d   Bak, Maarten ^a   Lataster, Tineke ^a   Lardinois, Mariëlle ^a   Delespaul, Philippe A E G ^a   Myin Germeys, Inez ^a,e  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d OPEN UNIVERSITY OF THE NETHERLANDS   (Netherlands)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; DOPAMINE 2 RECEPTOR; HALOPERIDOL; MOOD STABILIZER; OLANZAPINE; RISPERIDONE;

ADULT; AFFECT; AGED; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CONTROLLED STUDY; DELUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISSOCIATION CONSTANT; EMOTION; EXPERIENCE; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RECEPTOR BINDING; RECEPTOR OCCUPANCY;

EID: 80054901956     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05466yel     Document Type: Article

References (49)

1. Peroutka SJ, Synder SH. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry. 1980;137(12):1518-1522. PubMed (Pubitemid 11196805)
2. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1988;1(3):179-186. doi:10.1016/0893- 13X(8)9012-7 PubMed
3. Nordström AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl). 1992;106(4):433-438. doi:10.107/BF02481 PubMed
4. Kapur S. How antipsychotics become anti-"psychotic" - from dopamine to salience to psychosis. Trends Pharmacol Sci. 2004;25(8):402-406. doi:10.1016/j.tips.204.06.05 PubMed (Pubitemid 38981555)
5. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998;28(3):309-369. doi:10.1016/S0165-0173(98)019-8 PubMed (Pubitemid 29012677)
6. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160(1):13-23. doi:10.176/api.ajp.160.1.13 PubMed (Pubitemid 36042420)
7. Artaloytia JF, Arango C, Lahti A, et al. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry. 2006;163(3):488-493. doi:10.176/api.ajp.163.3.48 PubMed (Pubitemid 44469392)
8. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl). 2002;162(1): 3-10. doi:10.107/s0213-02-1052-z PubMed (Pubitemid 34639549)
9. de Haan L, van Bruggen M, Lavalaye J, et al. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry. 2003;160(2):303-309. doi:10.176/api.ajp.160.2.303 PubMed (Pubitemid 41110456)
10. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry. 1974;31(1):67-72. PubMed
11. Van Putten T, May PR, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry. 1981;38(2):187-190. PubMed (Pubitemid 11142771)
12. Ashleigh EA, Larsen PD. A syndrome of increased affect in response to risperidone among patients with schizophrenia. Psychiatr Serv. 1998; 49(4):526-528. PubMed (Pubitemid 28175693)
13. de Haan L, Lavalaye J, Linszen D, et al. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000;157(6): 1019-1020. doi:10.176/api.ajp.157.6.1019 PubMed (Pubitemid 30412360)
14. Mizrahi R, Rusjan P, Agid O, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry. 2007;164(4): 630-637. doi:10.176/api.ajp.164.4.630 PubMed (Pubitemid 46650195)
15. Voruganti L, Slomka P, Zabel P, et al. Subjective effects of AMPTinduced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology. 2001;25(5):642-650. doi:10.1016/S0893-13X(01)0263-9 PubMed
16. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand. 1994; 89(s380):27-32. doi:10.1/j.160-047.194.tb05828.x (Pubitemid 24147816)
17. Naber D, Karow A, Lambert M. Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand suppl. 2005;111(s42):29-34. doi:10.1/j.160-047.205.0542.xPubMed (Pubitemid 40780197)
18. Myin-Germeys I, Oorschot M, Collip D, et al. Experience sampling research in psychopathology: opening the black box of daily life. Psychol Med. 2009;39(9):1533-1547. doi:10.1017/S0329170804947 PubMed
19. Delespaul PAEG. Assessing Schizophrenia in Daily Life. Maastricht, The Netherlands: University Press Maastricht; 1995.
20. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998;3(2): 123-134. doi:10.1038/sj.mp.4036 PubMed (Pubitemid 28149553)
21. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry. 1999;156(6):876-884. PubMed (Pubitemid 29260342)
22. García-Cabeza I, Gómez JC, Sacristán JA, et al. Subjective response to antipsychotic treatment and compliance in schizophrenia: a naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry. 2001;1(1):7. doi:10.186/1471-24X-1-7 PubMed
23. The American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition, Text Revision. Washington, DC: The American Psychiatric Association; 2000.
24. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness: development and reliability of the OPCRIT system. Arch Gen Psychiatry. 1991;48(8):764-770. PubMed
25. Ventura J, Nuechterlein KH, Subotnik KL, et al. Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Res. 2000;97(2-3):129-135. doi:10.1016/S0165-1781(0)028-6 PubMed (Pubitemid 32126552)
26. Velligan D, Prihoda T, Dennehy E, et al. Brief psychiatric rating scale expanded version: how do new items affect factor structure? Psychiatry Res. 2005;135(3):217-228. doi:10.1016/j.psychres.205.05.01 PubMed (Pubitemid 40984613)
27. Moleman P. Practical Psychopharmacology. 4th edition. Houten, The Netherlands: Bohn Stafleu van Loghum; 2005:198-199.
28. Schwartz JE, Stone AA. Strategies for analyzing ecological momentary assessment data. Health Psychol. 1998;17(1):6-16. doi:10.1037/0278-613.17.1.6 PubMed (Pubitemid 28269765)
29. Stata/MP (for Windows) [computer program]. Version 10.0. College Station, TX: StataCorp; 2007.
30. Kongsakon R, Trinidad-Oñate P, Chaudhry HR, et al. Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol. J Med Assoc Thai. 2006;89(8):1157-1170. PubMed (Pubitemid 44358713)
31. Revicki DA, Genduso LA, Hamilton SH, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 1999;8(5):417-426. doi:10.1023/A:108958925848 PubMed (Pubitemid 29379026)
32. Mohr P. Quality of life in the long-term treatment and the role of second-generation antipsychotics. Neuroendocrinol Lett. 2007; 28(suppl 1):117-133. PubMed (Pubitemid 46534377)
33. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50(1-2):79-88. doi:10.1016/S0920-964(0)016-3 PubMed (Pubitemid 32510889)
34. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry. 2001;158(3):360-369. doi:10.176/api.ajp.158.3.360 PubMed (Pubitemid 32205190)
35. Canli T, Lesch KP. Long story short: the serotonin transporter in emotion regulation and social cognition. Nat Neurosci. 2007;10(9):1103-1109. doi:10.1038/n1964 PubMed (Pubitemid 47339957)
36. Maækowiak M, Czyrak A, Wedzony K. The involvement of 5-HT1a serotonin receptors in the pathophysiology and pharmacotherapy of schizophrenia. [Article in Polish] Psychiatr Pol. 2000;34(4):607-621. PubMed (Pubitemid 32124921)
37. Meltzer HY. The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol. 1995;15(suppl 1):2S-3S. PubMed
38. Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther. 2000;295(3):853-861. PubMed
39. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156(2):286-293. PubMed (Pubitemid 29077120)
40. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999;35(1):51-68. doi:10.1016/S0920-964(98)0105-4 PubMed (Pubitemid 29023554)
41. Peuskens J; Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995;166(6):712-726, discussion 727-733. doi:10.192/bjp.16.6.712 PubMed
42. Mauri MC, Moliterno D, Rossattini M, et al. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs. Schizophr Res. 2008;99(1-3):7-12. doi:10.1016/j.schres.207.10.020 PubMed (Pubitemid 351249117)
43. Lipkovich I, Baron D, Houston J, et al. Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments. J Clin Psychopharmacol. 2005;25(4):381-386. doi:10.1097/01.jcp.016791.7064.d4 PubMed (Pubitemid 41060261)
44. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-520. doi:10.176/api.ajp.157.4.514 PubMed (Pubitemid 30191189)
45. Karow A, Czekalla J, Dittmann RW, et al. Association of subjective wellbeing, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry. 2007;68(1):75-80. doi:10.408/JCP.v68n010 PubMed (Pubitemid 46220127)
46. Strauss JS. The person with schizophrenia as a person, II: approaches to the subjective and complex. Br J Psychiatry suppl. 1994;(23):103-107.PubMed (Pubitemid 24141713)
47. Stone AA, Shiffman S, Schwartz JE, et al. Patient compliance with paper and electronic diaries. Control Clin Trials. 2003;24(2):182-199. doi:10.1016/S0197-2456(02)0320-3 PubMed (Pubitemid 36412017)
48. Green AS, Rafaeli E, Bolger N, et al. Paper or plastic? data equivalence in paper and electronic diaries. Psychol Methods. 2006;11(1):87-105. doi:10.1037/1082-989X.1.1.87 PubMed (Pubitemid 44084653)
49. Jacobs N, Nicolson NA, Derom C, et al. Electronic monitoring of salivary cortisol sampling compliance in daily life. Life Sci. 2005;76(21): 2431-2443. doi:10.1016/j.lfs.204.10.045 PubMed (Pubitemid 40341960)